SEC Form 3 · accession 0000899243-18-030400
Moderna, Inc. · MRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Mendlein
Officer — See Remarks
Period of report
Dec 7, 2018
Accepted (ET)
Dec 7, 2018 · 5:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001682852
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 806,154 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.90 | holding | — | — | — | — | Feb 23, 2026 | Common Stock | 23,853 | — | D |
| Stock Option (Right to Buy)F2 | $19.15 | holding | — | — | — | — | Aug 10, 2026 | Common Stock | 9,263 | — | D |
| Stock Option (Right to Buy)F3 | $12.21 | holding | — | — | — | — | Feb 23, 2027 | Common Stock | 42,201 | — | D |
| Stock Option (Right to Buy)F4 | $14.22 | holding | — | — | — | — | Feb 28, 2028 | Common Stock | 2,981,651 | — | D |
Explanation of responses
- F1This option is fully vested and exercisable.
- F2This option is fully vested and exercisable.
- F3This option is fully vested and exercisable.
- F41,834,863 options will vest over 4 years, with 25% vesting on January 2, 2019, and the remaining 75% vesting in equal calendar quarterly installments over the next three years; 688,073 options will vest over 5 years, with 25% vesting on January 2, 2020, and the remaining 75% vesting in equal calendar quarterly installments over the following three years; and 458,715 options will vest over 6 years, with 25% vesting on January 2, 2021, and the remaining 75% vesting in equal calendar quarterly installments over the following three years.
Remarks
President, Corporate and Product Strategy Exhibit 24.1: Power of Attorney